WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark ITM was filed as Word mark on 07/28/2020 at the World Intellectual Property Organization.
| Trademark form | Word mark |
| File reference | 1555229 |
| Register number | 302020102333 |
| Countries | 
|
| Base trademark |
No. 30 2020 102 333,
May 5, 2020
|
| Application date | July 28, 2020 |
| Expiration date | July 28, 2030 |
Trademark owner
Lichtenbergstr. 1
85748 Garching
DE
85748 Garching
DE
Trademark representatives
Alois-Steinecker-Str. 22
85354 Freising
DE
goods and services
05
Radiopharmaceutical diagnostic and therapeutic preparations
for medical purposes, in particular radiopharmaceutical
preparations for endo-radionuclide therapy, brachytherapy
and radiopharmaceutical preparations for positron emission
tomography [PET] or single photon emission tomography
[SPECT], target radionuclide and peptide receptor
radionuclide therapy [PRRT]; theranostics in the field of
precision oncology; radiopharmaceutical products, namely
lutetium-containing precursors; solutions for radioactive
labelling; radiopharmaceutical preparations for use in
oncology, namely radiopharmaceuticals containing
radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90
for treatment and radioisotopes such as gallium-68 or
fluorine-18 for diagnosis of tumours; target
radiopharmaceuticals containing a target molecule, e.g.
peptide or antibody, depending on the indication and a
medical radioactive isotope; radiopharmaceuticals containing
gallium and its complexes, gallium-68 DOTATOC;
177Lu-edotreotide preparations for targeted radionuclide
therapy in patients with neuroendocrine tumours of
gastroenteric or pancreatic origin [GEP-NET];
radiopharmaceuticals for use in the therapy of GEP-NET,
osteosarcoma, bone metastases, prostate cancer, breast
cancer, brain cancer, ovarian cancer; radiopharmaceuticals
containing radioisotopes with short half-lives, such as
gallium-68 or fluorine-18 for diagnostic applications;
Radiopharmaceuticals for use with highly sensitive molecular
imaging technologies such as PET [positron emission
tomography] or SPECT [single photon emission tomography],
for the production of images of organs and lesions and for
the early diagnosis of diseases; radiopharmaceuticals
containing medical radioisotopes with longer half-lives, in
particular lutetium-177, actinium-225 or yttrium-90 for the
treatment of tumour diseases
10
Medical instruments, apparatus and containers for the
application of radiopharmaceutical and radiodiagnostic
preparations; controlling, regulating and measuring
apparatus as parts of medical instruments, apparatus and
containers included in this class, in particular apparatus
for therapy and diagnosis with a radiotherapeutic or
radiodiagnostic substance; radionuclide generators for
radiopharmaceutical purposes
42
Conducting clinical trials at all stages and in various
indications, particularly in oncology; conducting phase III
clinical trials with target radiopharmaceutical
177Lu-Edotreotide in patients with neuroendocrine tumours of
gastroenteric or pancreatic origin [GEP-NET]
44
Medical services, in particular services relating to
radiotherapeutic and radiodiagnostic oncology, cardiology,
angiology, neuroradiology and nuclear medicine and
brachytherapies, including intercavitary, interstitial and
intravascular brachytherapy, radionuclide labelling, PET and
SPECT scanning and target radionuclide therapy, peptide
receptor radionuclide therapy [PRRT], personal nuclear
medicine and precision oncology
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| November 16, 2022 | 2022/51 Gaz | CA | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| July 21, 2022 | 2022/30 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| June 29, 2022 | 2022/27 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| January 27, 2022 | 2022/6 Gaz | MX | Rejection |
| January 25, 2022 | 2022/5 Gaz | CA | Rejection |
| December 1, 2021 | 2022/4 Gaz | AU | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| October 4, 2021 | 2021/40 Gaz | RU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| October 4, 2021 | 2021/43 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| September 23, 2021 | 2021/40 Gaz | JP | Rejection |
| September 14, 2021 | 2021/37 Gaz | CH | Rejection |
| September 3, 2021 | 2021/35 Gaz | NO | Rejection |
| September 1, 2021 | 2021/36 Gaz | KR | Rejection |
| August 19, 2021 | 2021/35 Gaz | CO | Rejection |
| June 8, 2021 | 2021/24 Gaz | BR | Rejection |
| May 31, 2021 | 2021/34 Gaz | RAW: Limitation | |
| April 21, 2021 | 2021/17 Gaz | CO | Rejection |
| March 31, 2021 | 2021/13 Gaz | TR | Rejection |
| March 4, 2021 | 2021/10 Gaz | EM | Rejection |
| January 25, 2021 | 2021/4 Gaz | RU | Rejection |
| December 4, 2020 | 2020/50 Gaz | US | Rejection |
| November 19, 2020 | 2020/48 Gaz | AU | Rejection |
| October 26, 2020 | 2020/45 Gaz | IN | Rejection |
| July 28, 2020 | 2020/40 Gaz | DE | Registration |
ID: 141555229